A University of California, Riverside, study has identified the biological underpinnings of a reproductive disorder caused by the mutation of a gene. This gene mutation also causes Fragile X Syndrome, a leading genetic cause of intellectual impairment and autism. The researchers found mutations of the Fragile X messenger ribonucleoprotein 1 gene, or FMR1, contribute to
0 Comments
Michael Regan, administrator of the Environmental Protection Agency (EPA), speaks during an event at the EPA headquarters in Washington, D.C., U.S., on Monday, Dec. 20, 2021. Samuel Corum | Bloomberg | Getty Images The Environmental Protection Agency on Wednesday said it will strengthen limits on several toxic air pollutants emitted by power plants, including mercury, a
0 Comments
In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma. The findings, published today
0 Comments
When the Biden administration killed the X waiver late last year, all clinicians registered with the Drug Enforcement Administration (DEA) learned they would need 8 hours of training on substance use disorder (SUD) management in order to renew their licenses. The DEA has now issued a deadline for that requirement, and it’s less than 3
0 Comments
The youngest patient with cannabis-induced psychosis (CIP) whom Karen Randall, DO, has treated was a 7-year-old boy. She remembers the screaming, the yelling, the uncontrollable rage. Randall is an emergency medicine physician at Southern Colorado Emergency Medicine Associates, a group practice in Pueblo, Colorado. She treats youth for cannabis-related medical problems in the emergency department
0 Comments
Isaac Kohane, founding chair of the Department of Biomedical Informatics (DBMI) in the Blavatnik Institute at Harvard Medical School, discusses efficacy testing of artificial intelligence widgets and his appointment as editor-in-chief of the inaugural New England Journal of Medicine AI. Connect with Dr. Kohane on social media and continue the conversation: Twitter: https://bit.ly/ZakKohaneTwitter LinkedIn: https://bit.ly/ZakKohaneLinkedin
0 Comments
Editor’s Note: Get inspired by a weekly roundup on living well, made simple. Sign up for CNN’s Life, But Better newsletter for information and tools designed to improve your well-being. CNN  —  Alzheimer’s disease strikes women harder than men — over two-thirds of those who descend into dementia’s devastating twilight are female at birth. That’s
0 Comments
(Reuters) – A Delaware judge on Monday dismissed Merck & Co’s lawsuit seeking to hold Bayer AG responsible for more talc-related liabilities stemming from its $14.2 billion purchase of Merck’s consumer care business in 2014. Vice Chancellor Nathan Cook of the Delaware Chancery Court said the purchase agreement “clearly and unambiguously” left Merck liable for
0 Comments
LEIDEN, Netherlands, April 3, 2023. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases, today announced that the first patient has been dosed in a Phase 1/2a clinical study evaluating VO659 for the treatment of Huntington’s disease (HD), spinocerebellar ataxia type 1 (SCA1) and type 3 (SCA3). VO659 is an
0 Comments
In this article ILMN Follow your favorite stocksCREATE FREE ACCOUNT Francis deSouza, chief executive officer of Illumina Inc., during a panel session on day three of the World Economic Forum (WEF) in Davos, Switzerland, on Thursday, Jan. 19, 2023. Stefan Wermuth | Bloomberg | Getty Images The Federal Trade Commission on Monday ordered Illumina to
0 Comments
The FDA gave accelerated approval to enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) as first-line treatment for certain patients with locally advanced or metastatic urothelial cancer, the agency announced on Monday. Specifically, the combination is indicated for those who are ineligible for cisplatin-containing chemotherapy, and the approval marks the first anti-PD-1/antibody-drug conjugate combination for this patient
0 Comments
We get a lot of questions from readers about what you can do to help a hospitalized family member or friend. Patients love the sentiment, but most have their fill of robes, fluffy slippers and lavender scented lotions and potions. Recently, friends of OncoLink, Stephanie and Whitney, shared with me what they did for their
0 Comments
Over-the-scope clips (OTSC) may prevent further bleeding more so than standard endoscopic treatment when used as primary treatment in patients with high-risk nonvariceal upper gastrointestinal lesions, shows a randomized controlled trial (RCT). However, noted the investigators, writing in Annals of Internal Medicine, and physicians who wrote an accompanying editorial, reservations remain about first-line use of OTSCs, but mostly
0 Comments
RAHWAY, N.J.–(BUSINESS WIRE) April 3, 2023 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC)
0 Comments
As well as recently celebrating Cancer Research UK’s 20th birthday, this year also marks 20 years of our Flame of Hope Awards. The Flame of Hope Awards are our annual celebration of our most outstanding and dedicated supporters and volunteers. Since the first ceremony in 2003 we’ve presented almost 2000 awards to thank the amazing
0 Comments
NEW ORLEANS — More than one third of pediatric residency programs do not have a pediatric rheumatologist on faculty, a situation that has changed little since 2004, according to a poster presented at the Pediatric Rheumatology Symposium 2023 conference. “This shortage has significant downstream effects,” according to author Miriah Gillispie-Taylor, MD, an assistant professor of
0 Comments
Today’s Kidney Dialysis Options for People With Diabetes – Diabetes Daily Learning Center Learning Center: LearningCenter Diabetes Daily does not provide medical advice,diagnosis or treatment.Get additional information.© 2005 – 2023 Everyday Health, Inc., a Ziff Davis company. Everyday Health is among the federally registered trademarks of Everyday Health, Inc. and may not be used by
0 Comments